Literature DB >> 15479826

Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging.

Kun Luo1, Bindong Liu, Zuoxiang Xiao, Yunkai Yu, Xianghui Yu, Robert Gorelick, Xiao-Fang Yu.   

Abstract

APOBEC3G exerts its antiviral activity by targeting to retroviral particles and inducing viral DNA hypermutations in the absence of Vif. However, the mechanism by which APOBEC3G is packaged into virions remains unclear. We now report that viral genomic RNA enhances but is not essential for human APOBEC3G packaging into human immunodeficiency virus type 1 (HIV-1) virions. Packaging of APOBEC3G was also detected in HIV-1 Gag virus-like particles (VLP) that lacked all the viral genomic RNA packaging signals. Human APOBEC3G could be packaged efficiently into a divergent subtype HIV-1, as well as simian immunodeficiency virus, strain mac, and murine leukemia virus Gag VLP. Cosedimentation of human APOBEC3G and intracellular Gag complexes was detected by equilibrium density and velocity sucrose gradient analysis. Interaction between human APOBEC3G and HIV-1 Gag was also detected by coimmunoprecipitation experiments. This interaction did not require p6, p1, or the C-terminal region of NCp7. However, the N-terminal region, especially the first 11 amino acids, of HIV-1 NCp7 was critical for HIV-1 Gag and APOBEC3G interaction and virion packaging. The linker region flanked by the two active sites of human APOBEC3G was also important for efficient packaging into HIV-1 Gag VLP. Association of human APOBEC3G with RNA-containing intracellular complexes was observed. These results suggest that the N-terminal region of HIV-1 NC, which is critical for binding to RNA and mediating Gag-Gag oligomerization, plays an important role in APOBEC3G binding and virion packaging.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15479826      PMCID: PMC523292          DOI: 10.1128/JVI.78.21.11841-11852.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  95 in total

1.  An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22.

Authors:  Adam Jarmuz; Ann Chester; Jayne Bayliss; Jane Gisbourne; Ian Dunham; James Scott; Naveenan Navaratnam
Journal:  Genomics       Date:  2002-03       Impact factor: 5.736

2.  Structural and functional properties of the HIV-1 RNA-tRNA(Lys)3 primer complex annealed by the nucleocapsid protein: comparison with the heat-annealed complex.

Authors:  Fabienne Brulé; Roland Marquet; Liwei Rong; Mark A Wainberg; Bernard P Roques; Stuart F J Le Grice; Bernard Ehresmann; Chantal Ehresmann
Journal:  RNA       Date:  2002-01       Impact factor: 4.942

3.  Mechanism for nucleic acid chaperone activity of HIV-1 nucleocapsid protein revealed by single molecule stretching.

Authors:  M C Williams; I Rouzina; J R Wenner; R J Gorelick; K Musier-Forsyth; V A Bloomfield
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

Review 4.  Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business.

Authors:  Joseph E Wedekind; Geoffrey S C Dance; Mark P Sowden; Harold C Smith
Journal:  Trends Genet       Date:  2003-04       Impact factor: 11.639

5.  Nucleic acid-independent retrovirus assembly can be driven by dimerization.

Authors:  Marc C Johnson; Heather M Scobie; Yu May Ma; Volker M Vogt
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

6.  Isolation, characterization and developmental regulation of the human apobec-1 complementation factor (ACF) gene.

Authors:  J O Henderson; V Blanc; N O Davidson
Journal:  Biochim Biophys Acta       Date:  2001-11-11

7.  Two proteins essential for apolipoprotein B mRNA editing are expressed from a single gene through alternative splicing.

Authors:  Geoffrey S C Dance; Mark P Sowden; Luca Cartegni; Ellen Cooper; Adrian R Krainer; Harold C Smith
Journal:  J Biol Chem       Date:  2002-01-28       Impact factor: 5.157

8.  Specific incorporation of heat shock protein 70 family members into primate lentiviral virions.

Authors:  Cagan Gurer; Andrea Cimarelli; Jeremy Luban
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

9.  Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.

Authors:  Ann M Sheehy; Nathan C Gaddis; Jonathan D Choi; Michael H Malim
Journal:  Nature       Date:  2002-07-14       Impact factor: 49.962

10.  HIV-1 nucleocapsid protein as a nucleic acid chaperone: spectroscopic study of its helix-destabilizing properties, structural binding specificity, and annealing activity.

Authors:  María A Urbaneja; Min Wu; José R Casas-Finet; Richard L Karpel
Journal:  J Mol Biol       Date:  2002-05-03       Impact factor: 5.469

View more
  113 in total

1.  Association of potent human antiviral cytidine deaminases with 7SL RNA and viral RNP in HIV-1 virions.

Authors:  Wenyan Zhang; Juan Du; Kevin Yu; Tao Wang; Xiong Yong; Xiao-Fang Yu
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

Review 2.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

Review 3.  Features, processing states, and heterologous protein interactions in the modulation of the retroviral nucleocapsid protein function.

Authors:  Gilles Mirambeau; Sébastien Lyonnais; Robert J Gorelick
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

Review 4.  Function of a retrotransposon nucleocapsid protein.

Authors:  Suzanne B Sandmeyer; Kristina A Clemens
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

5.  The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication.

Authors:  Xiaoxia Wang; Zhujun Ao; Liyu Chen; Gary Kobinger; Jinyu Peng; Xiaojian Yao
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

Review 6.  Emerging drug targets for antiretroviral therapy.

Authors:  Jacqueline D Reeves; Andrew J Piefer
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.

Authors:  Judd F Hultquist; Reuben S Harris
Journal:  Future Virol       Date:  2009-11-01       Impact factor: 1.831

8.  Characterization of anti-HIV activity mediated by R88-APOBEC3G mutant fusion proteins in CD4+ T cells, peripheral blood mononuclear cells, and macrophages.

Authors:  Zhujun Ao; Xiaoxia Wang; Alexander Bello; Kallesh Danappa Jayappa; Zhe Yu; Keith Fowke; Xinying He; Xi Chen; Junhua Li; Gary Kobinger; Xiaojian Yao
Journal:  Hum Gene Ther       Date:  2011-03-18       Impact factor: 5.695

9.  CBFβ enhances de novo protein biosynthesis of its binding partners HIV-1 Vif and RUNX1 and potentiates the Vif-induced degradation of APOBEC3G.

Authors:  Eri Miyagi; Sandra Kao; Venkat Yedavalli; Klaus Strebel
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

10.  Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation.

Authors:  Hal P Bogerd; Bryan R Cullen
Journal:  RNA       Date:  2008-05-02       Impact factor: 4.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.